MRD Strategic Steering Working Group

Angela Silvestro

Director of Companion Diagnostics

GSK

Co-Chairs

Jim Godsey, PhD

Scientific Co-Chair

BLOODPAC

Current Projects

The MRD Strategic Steering WG is working on defining the next MRD projects:

  • Demonstrate MRD Clinical Utility: Launch a new WG to focus on demonstrating the clinical utility of MRD testing, complementing ongoing efforts on MRD clinical validation approaches.

  • Support guideline integration: Develop recommendations and guidance to accelerate inclusion of solid tumor MRD intended uses in the NCCN Guidelines.

  • Pursue Surrogate Endpoint designation: Create a dedicated WG to advance MRD testing toward Surrogate Endpoint status in adjuvant therapy trials, strengthening the link between MRD results and long-term patient outcomes.

Participating Organizations

Adela, Biofidelity, Bristol Myers Squibb, Exact Sciences, Freenome, Friends of Cancer Research, GSK, Guardant Health, Johnson & Johnson, Merck, Natera, NeoGenomics, PreAnalytiX, Roche

Past Deliverables

Meetings

This working group meets on zoom every other *** from *** - *** PM EST.

Special workshops and sessions:

June 25, 2025: In-person workshop in Boston